Literature DB >> 21837760

NATb/NAT1*4 promotes greater arylamine N-acetyltransferase 1 mediated DNA adducts and mutations than NATa/NAT1*4 following exposure to 4-aminobiphenyl.

Lori M Millner1, Mark A Doll, Jian Cai, J Christopher States, David W Hein.   

Abstract

N-acetyltransferase 1 (NAT1) is a phase II metabolic enzyme responsible for the biotransformation of aromatic and heterocyclic amine carcinogens such as 4-aminobiphenyl (ABP). NAT1 catalyzes N-acetylation of arylamines as well as the O-acetylation of N-hydroxylated arylamines. O-acetylation leads to the formation of electrophilic intermediates that result in DNA adducts and mutations. NAT1 is transcribed from a major promoter, NATb, and an alternative promoter, NATa, resulting in mRNAs with distinct 5'-untranslated regions (UTR). NATa mRNA is expressed primarily in the kidney, liver, trachea, and lung while NATb mRNA has been detected in all tissues studied. To determine if differences in 5'-UTR have functional effect upon NAT1 activity and DNA adducts or mutations following exposure to ABP, pcDNA5/FRT plasmid constructs were prepared for transfection of full-length human mRNAs including the 5'-UTR derived from NATa or NATb, the open reading frame, and 888 nucleotides of the 3'-UTR. Following stable transfection of NATb/NAT1*4 or NATa/NAT1*4 into nucleotide excision repair (NER) deficient Chinese hamster ovary cells, N-acetyltransferase activity (in vitro and in situ), mRNA, and protein expression were higher in NATb/NAT1*4 than NATa/NAT1*4 transfected cells (P < 0.05). Consistent with NAT1 expression and activity, ABP-induced DNA adducts and hypoxanthine phosphoribosyl transferase mutants were significantly higher (P < 0.05) in NATb/NAT1*4 than in NATa/NAT1*4 transfected cells following exposure to ABP. These differences observed between NATa and NATb suggest that the 5'-UTRs are differentially regulated.
Copyright © 2011 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21837760      PMCID: PMC3217153          DOI: 10.1002/mc.20836

Source DB:  PubMed          Journal:  Mol Carcinog        ISSN: 0899-1987            Impact factor:   4.784


  50 in total

1.  Single molecule analysis of RNA polymerase elongation reveals uniform kinetic behavior.

Authors:  Karen Adelman; Arthur La Porta; Thomas J Santangelo; John T Lis; Jeffrey W Roberts; Michelle D Wang
Journal:  Proc Natl Acad Sci U S A       Date:  2002-10-07       Impact factor: 11.205

2.  Specificity of microRNA target selection in translational repression.

Authors:  John G Doench; Phillip A Sharp
Journal:  Genes Dev       Date:  2004-03-10       Impact factor: 11.361

3.  Nascent RNA sequencing reveals widespread pausing and divergent initiation at human promoters.

Authors:  Leighton J Core; Joshua J Waterfall; John T Lis
Journal:  Science       Date:  2008-12-04       Impact factor: 47.728

4.  Permanent hair dyes and bladder cancer: risk modification by cytochrome P4501A2 and N-acetyltransferases 1 and 2.

Authors:  Manuela Gago-Dominguez; Douglas A Bell; Mary A Watson; Jian-Min Yuan; J Esteban Castelao; David W Hein; Kenneth K Chan; Gerhard A Coetzee; Ronald K Ross; Mimi C Yu
Journal:  Carcinogenesis       Date:  2003-03       Impact factor: 4.944

5.  Arylamine N-acetyltransferase-1 is highly expressed in breast cancers and conveys enhanced growth and resistance to etoposide in vitro.

Authors:  Paul J Adam; Joanne Berry; Julie A Loader; Kerry L Tyson; Graham Craggs; Paul Smith; Jackie De Belin; Graham Steers; Francesco Pezzella; Kris F Sachsenmeir; Alasdair C Stamps; Athula Herath; Edith Sim; Michael J O'Hare; Adrian L Harris; Jonathan A Terrett
Journal:  Mol Cancer Res       Date:  2003-09       Impact factor: 5.852

6.  Arylamine N-acetyltransferase 1 expression in breast cancer cell lines: a potential marker in estrogen receptor-positive tumors.

Authors:  Larissa Wakefield; James Robinson; Hilary Long; J Claire Ibbitt; Susanna Cooke; Helen C Hurst; Edith Sim
Journal:  Genes Chromosomes Cancer       Date:  2008-02       Impact factor: 5.006

Review 7.  The functional consequences of alternative promoter use in mammalian genomes.

Authors:  Ramana V Davuluri; Yutaka Suzuki; Sumio Sugano; Christoph Plass; Tim H-M Huang
Journal:  Trends Genet       Date:  2008-03-07       Impact factor: 11.639

8.  Meat intake, heterocyclic amine exposure, and metabolizing enzyme polymorphisms in relation to colorectal polyp risk.

Authors:  Aesun Shin; Martha J Shrubsole; Jeffrey M Rice; Qiuyin Cai; Mark A Doll; Jirong Long; Walter E Smalley; Yu Shyr; Rashmi Sinha; Reid M Ness; David W Hein; Wei Zheng
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-02       Impact factor: 4.254

9.  Interaction of the cytochrome P4501A2, SULT1A1 and NAT gene polymorphisms with smoking and dietary mutagen intake in modification of the risk of pancreatic cancer.

Authors:  Hideo Suzuki; Jeffrey S Morris; Yanan Li; Mark A Doll; David W Hein; Jun Liu; Li Jiao; Manal M Hassan; Rena S Day; Melissa L Bondy; James L Abbruzzese; Donghui Li
Journal:  Carcinogenesis       Date:  2008-05-21       Impact factor: 4.944

10.  Deletion of a xenobiotic metabolizing gene in mice affects folate metabolism.

Authors:  Larissa Wakefield; Valerie Cornish; Hilary Long; William J Griffiths; Edith Sim
Journal:  Biochem Biophys Res Commun       Date:  2007-10-15       Impact factor: 3.575

View more
  13 in total

1.  Genetic and small molecule inhibition of arylamine N-acetyltransferase 1 reduces anchorage-independent growth in human breast cancer cell line MDA-MB-231.

Authors:  Marcus W Stepp; Mark A Doll; Samantha M Carlisle; J Christopher States; David W Hein
Journal:  Mol Carcinog       Date:  2018-02-03       Impact factor: 4.784

2.  Phenotype of the most common "slow acetylator" arylamine N-acetyltransferase 1 genetic variant (NAT1*14B) is substrate-dependent.

Authors:  Lori M Millner; Mark A Doll; Jian Cai; J Christopher States; David W Hein
Journal:  Drug Metab Dispos       Date:  2011-10-18       Impact factor: 3.922

3.  Untargeted polar metabolomics of transformed MDA-MB-231 breast cancer cells expressing varying levels of human arylamine N-acetyltransferase 1.

Authors:  Samantha M Carlisle; Patrick J Trainor; Xinmin Yin; Mark A Doll; Marcus W Stepp; J Christopher States; Xiang Zhang; David W Hein
Journal:  Metabolomics       Date:  2016-06-21       Impact factor: 4.290

4.  Reduced 4-aminobiphenyl-induced liver tumorigenicity but not DNA damage in arylamine N-acetyltransferase null mice.

Authors:  Kim S Sugamori; Debbie Brenneman; Otto Sanchez; Mark A Doll; David W Hein; William M Pierce; Denis M Grant
Journal:  Cancer Lett       Date:  2011-12-19       Impact factor: 8.679

5.  Identification and characterization of potent, selective, and efficacious inhibitors of human arylamine N-acetyltransferase 1.

Authors:  Carmine S Leggett; Mark A Doll; Raúl A Salazar-González; Mariam R Habil; John O Trent; David W Hein
Journal:  Arch Toxicol       Date:  2021-11-16       Impact factor: 5.153

6.  N-acetyltransferase 2 genetic polymorphism modifies genotoxic and oxidative damage from new psychoactive substances.

Authors:  Raúl A Salazar-González; Mark A Doll; David W Hein
Journal:  Arch Toxicol       Date:  2022-09-23       Impact factor: 6.168

7.  High N-Acetyltransferase 1 Expression Is Associated with Estrogen Receptor Expression in Breast Tumors, but Is not Under Direct Regulation by Estradiol, 5α-androstane-3β,17β-Diol, or Dihydrotestosterone in Breast Cancer Cells.

Authors:  Xiaoyan Zhang; Samantha M Carlisle; Mark A Doll; Robert C G Martin; J Christopher States; Carolyn M Klinge; David W Hein
Journal:  J Pharmacol Exp Ther       Date:  2018-01-16       Impact factor: 4.030

8.  Functional analysis of arylamine N-acetyltransferase 1 (NAT1) NAT1*10 haplotypes in a complete NATb mRNA construct.

Authors:  Lori M Millner; Mark A Doll; Marcus W Stepp; J Christopher States; David W Hein
Journal:  Carcinogenesis       Date:  2011-11-22       Impact factor: 4.944

9.  Acetylation of putative arylamine and alkylaniline carcinogens in immortalized human fibroblasts transfected with rapid and slow acetylator N-acetyltransferase 2 haplotypes.

Authors:  Carmine S Leggett; Mark A Doll; J Christopher States; David W Hein
Journal:  Arch Toxicol       Date:  2020-11-02       Impact factor: 5.153

10.  Identification of cancer chemopreventive isothiocyanates as direct inhibitors of the arylamine N-acetyltransferase-dependent acetylation and bioactivation of aromatic amine carcinogens.

Authors:  Romain Duval; Ximing Xu; Linh-Chi Bui; Cécile Mathieu; Emile Petit; Kevin Cariou; Robert H Dodd; Jean-Marie Dupret; Fernando Rodrigues-Lima
Journal:  Oncotarget       Date:  2016-02-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.